The phase II CAVALLI clinical trial demonstrated 80% PFS in DLBCL patients treated with venetoclax/R-CHOP versus 67% in the R-CHOP treated cohort, and 78% PFS versus 61% in the BCL2 IHC-positive group, with no significant differences in 2-year OS [147]. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.